Canaccord raised the firm’s price target on Regulus to $28 from $11 and keeps a Buy rating on the shares. The firm noted they announced topline data from Cohort 3 (n=16, 3mg/kg) of the Ph1b MAD study in RGLS8429 for ADPKD. Canaccord said the data announced today represents a large step forward in confirming the highly differentiated efficacy and safety profile for RGLS8429.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGLS: